Clinical study of arolol hydrochloride in the treatment of middle-aged and young people with essential hypertension

Based on the 2017 ACC/AHA guidelines, arolol hydrochloride in the treatment of young and middle-aged essential hypertension: a multicenter, randomized, open-label, active drug-controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049628

Enrollment

Unknown

Registered

2021-08-07

Start date

2021-12-31

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Interventions

Experimental group:Arotinolol hydrochloride

Control group 1:Metoprolol succinate

Control group 2:Atenolol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Newly treated patients with essential hypertension, diagnosed in accordance with the ''2017 ACC/AHA Guidelines for the Prevention, Detection, Evaluation and Management of Hypertension in American Adults'', the average sitting diastolic blood pressure in the office is >=90mmHg, and the average sitting systolic blood pressure in the office is 80 beats/min; 3. Aged 18-65 years, no gender limit; 4. Sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Have ever taken antihypertensive drugs; 2. Recently taking amiodarone greater than 200mg/day to control arrhythmia or taking class I antiarrhythmic drugs; 3. Patients with diagnosed atrioventricular block (?, ? degree), sinoatrial block, sick sinus syndrome; 4. Patients with severe cardiac insufficiency: New York Heart Association (NYHA) grade II and above; 5. History of new myocardial infarction and stroke within the past 3 months; 6. Severe liver and kidney disease: ALT and AST are greater than 2.5 times the upper limit of normal, and serum creatinine is greater than 3 mg/dl (265 µmol/L); 7. History of idiopathic hypoglycemia, uncontrolled diabetes patients (HbA1c>7%), and clinical diagnosis with pathological significance; 8. Patients with a history of bronchial asthma or chronic obstructive pulmonary disease; 9. Allergy to the study drug or other contraindications to the instructions; 10. Pregnant patients, lactating patients, and patients of childbearing age who are unwilling to take contraceptive measures; 11. Participate in other clinical research patients; 12. Patients judged by the investigator to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Blood pressure;	—

Secondary

Measure	Time frame
Heart rate;Fasting blood sugar;Glycated hemoglobin;Total cholesterol;Triglycerides;High density lipoprotein;Low-density lipoprotein;Urine microalbumin/creatinine ratio;Glomerular filtration rate;Long-term blood pressure variability;	—

Countries

China

Contacts

Public ContactSun Yingxian

The First Affiliated Hospital of China Medical University

2680481161@qq.com+86 13804068889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026